Foamix Pharmaceuticals Ltd (FOMX) CEO David Domzalski Sells 5,096 Shares

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) CEO David Domzalski sold 5,096 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $3.75, for a total transaction of $19,110.00. Following the completion of the transaction, the chief executive officer now owns 214,595 shares in the company, valued at $804,731.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of NASDAQ:FOMX opened at $3.22 on Friday. Foamix Pharmaceuticals Ltd has a one year low of $3.13 and a one year high of $7.60. The firm has a market capitalization of $173.99 million, a PE ratio of -1.89 and a beta of 1.70.

Institutional investors and hedge funds have recently made changes to their positions in the business. Federated Investors Inc. PA purchased a new stake in Foamix Pharmaceuticals during the 3rd quarter valued at $287,000. ETF Managers Group LLC lifted its position in shares of Foamix Pharmaceuticals by 66.6% in the 4th quarter. ETF Managers Group LLC now owns 81,972 shares of the specialty pharmaceutical company’s stock worth $294,000 after purchasing an additional 32,773 shares during the period. Eversept Partners LP lifted its position in shares of Foamix Pharmaceuticals by 7.7% in the 4th quarter. Eversept Partners LP now owns 294,660 shares of the specialty pharmaceutical company’s stock worth $1,058,000 after purchasing an additional 21,093 shares during the period. Stonepine Capital Management LLC lifted its position in shares of Foamix Pharmaceuticals by 134.7% in the 4th quarter. Stonepine Capital Management LLC now owns 1,293,177 shares of the specialty pharmaceutical company’s stock worth $4,643,000 after purchasing an additional 742,099 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Foamix Pharmaceuticals in the 3rd quarter worth about $6,616,000. 59.61% of the stock is owned by institutional investors and hedge funds.

FOMX has been the topic of a number of research analyst reports. Cowen set a $30.00 target price on shares of Foamix Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, March 1st. HC Wainwright set a $12.00 target price on shares of Foamix Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, January 4th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $15.00 price target on shares of Foamix Pharmaceuticals in a research note on Tuesday, April 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Foamix Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $14.75.

TRADEMARK VIOLATION NOTICE: “Foamix Pharmaceuticals Ltd (FOMX) CEO David Domzalski Sells 5,096 Shares” was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/26/david-domzalski-sells-5096-shares-of-foamix-pharmaceuticals-ltd-fomx-stock.html.

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.

Featured Article: Municipal Bonds

Insider Buying and Selling by Quarter for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.